Defining the Normal Range of Postprandial Metabolic Risk: Multi-omic and multi-tissue Analysis after a Mixed Meal - PROJECT SUMMARY
Cardiovascular disease (CVD) and Type 2 diabetes (T2D) are increasing in all developed and developing
countries, but the increase is especially severe in people of Mexican ancestry, whether in the US or in Mexico.
It is understood that these increases are due in part to effects of excess or unhealthy nutrition, implying that
variation in cardiometabolic disease risk may be due to variation in the capacity to manage a nutritional load.
However, few studies have examined postprandial metabolism, where this variation should be most evident.
Our colleagues in the GEMM Family Study (Genética de las Enfermedades Metabólicas en México, or
Genetics of Metabolic Diseases in Mexico), a multi-center study conducted by 10 university-based teaching
hospitals, have an ongoing recruitment of healthy urban adults who volunteer for a novel meal challenge. Each
participant receives a mixed meal, representing a healthy combination of carbohydrate, fats, and protein,
individually dosed as 30% of daily energy expenditure, and provides a timecourse series of blood and tissue
biopsy samples at fasting and for 5 hours after the meal. In this study, we propose to conduct comprehensive
molecular profiling, including conventional biochemical phenotypes in blood (insulin, glucose, free fatty acids,
etc.) to define variation in postprandial response, plus comprehensive metabolomic profiling in blood and
transcriptomic, proteomic, and metabolomic profiling in skeletal muscle, a key tissue for insulin response and
utilization of carbohydrate and free fatty acids. We expect to characterize postprandial response at
unprecedented resolution – establishing individual trajectories of established and novel biomarkers of
metabolic activity in blood and using combined “omics” data to identify pathways and genes involved in
postprandial response in muscle. We expect this information to help us define the range of variation in
metabolic flexibility, and therefore the risk of cardiometabolic disease, in nominally healthy individuals. We
further expect to identify novel biomarkers of cardiometabolic risk and to expand our knowledge of the
biological mechanisms of metabolic flexibility, as a basis for novel approaches to preventing and treating these
serious pathologies in a population at elevated risk of CVD and T2D. These findings should have a positive
impact on public health initiatives for dealing with these serious conditions, both in Mexico and in the rapidly-
growing Mexican American community.
